Compare MDGL & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | KD |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 6.2B |
| IPO Year | N/A | N/A |
| Metric | MDGL | KD |
|---|---|---|
| Price | $605.59 | $27.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $580.77 | $39.60 |
| AVG Volume (30 Days) | 298.4K | ★ 1.9M |
| Earning Date | 11-04-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.68 |
| Revenue | $740,640,000.00 | ★ $15,008,000,000.00 |
| Revenue This Year | $435.63 | $6.40 |
| Revenue Next Year | $52.56 | $3.60 |
| P/E Ratio | ★ N/A | $16.17 |
| Revenue Growth | ★ 864.21 | N/A |
| 52 Week Low | $265.00 | $23.28 |
| 52 Week High | $609.98 | $44.20 |
| Indicator | MDGL | KD |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 57.29 |
| Support Level | $535.33 | $26.06 |
| Resistance Level | $609.98 | $27.47 |
| Average True Range (ATR) | 20.86 | 0.69 |
| MACD | -0.56 | 0.15 |
| Stochastic Oscillator | 93.68 | 67.00 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.